Ranbaxy Wants In On Mylan's Suit Over Valsartan Exclusivity

Law360, New York (October 15, 2012, 3:21 PM EDT) -- Ranbaxy Laboratories Ltd. on Friday asked a Washington federal court to allow it to intervene in a Mylan Pharmaceuticals Inc. generic exclusivity dispute with the U.S. Food and Drug Administration over hypertension drug valsartan, saying only it could properly defend its exclusive rights to the drug.

According to the drugmaker’s motion to intervene in the suit, brought by Mylan on Oct. 2, it was the first company to file an abbreviated new drug application with the FDA to manufacture generic valsartan, meaning it was entitled to...
To view the full article, register now.